Bryleos的封面图片
Bryleos

Bryleos

生物技术研究

Johnson City,Tennessee 157 位关注者

BRY101 is metabolic modulator engineered to increase intracellular NAD pools for neurological diseases of aging

关于我们

Early clinical stage therapeutics company developing BRY101, a metabolic modulator engineered to increase intracellular NAD, impacting mitochondrial dysfunction, neuroinflammation and oxidative stress. BRY101 impacts multiple pathways simultaneously, breaking away from the traditional single-target drug development model. This strategy is designed to address the complex mechanisms involved in neurodegenerative and neuromuscular disorders. Bryleos: More Life While Living

网站
www.bryleos.com
所属行业
生物技术研究
规模
2-10 人
总部
Johnson City,Tennessee
类型
私人持股
创立
2021
领域
neuroscience、Parkinson's、Alzheimer's、Multiple Sclerosis、neuropsychiatry、Metabolic Disorder和ALS

地点

  • 主要

    207 North Boone Street

    Suite 15

    US,Tennessee,Johnson City,37604

    获取路线

Bryleos员工

动态

  • 查看Bryleos的组织主页

    157 位关注者

    We had the incredible opportunity to present our poster at #ARDD2024 in Copenhagen last month, and what an extraordinary experience it was to be amongst such forward-thinking individuals. Our poster, Pharmacodynamic Potential of Orally Bioavailable NAD+ in Diseases of Aging: Results from a Multi-Omic RCT in Aging Adults, sparked meaningful discussions around the role of NAD+ in longevity and diseases of aging. We are excited to share this research with the global scientific community and look forward to continuing our efforts to enhance health and longevity through our development of our lead asset, BRY101, a metabolic modulator engineered to increase intracellular NAD targeting neuroinflammation, mitochondrial dysfunction, and oxidative stress. #ARDD2024 #Insilico #PandaOmics #longevity

相似主页

融资

Bryleos 共 1 轮

上一轮

种子轮

US$5,000,000.00

投资者

Eddie Jordan
Crunchbase 上查看更多信息